KalVista Pharmaceuticals (NASDAQ:KALV) today reported financial results for the abbreviated fiscal period ended December 31, 2025, marking the company’s formal transition from a clinical-stage developer to a commercial-stage biopharmaceutical entity.
As part of this evolution, the company has officially changed its fiscal year-end from April 30 to December 31 to better align with standard commercial reporting cycles.
For the eight-month period ended December 31, 2025, KalVista recognized $49.1 million in net product revenue, almost entirely driven by the market introduction of EKTERLY, the company's treatment for hereditary angioedema (HAE).
The cost of revenue for this period remained lean at $3.1 million, highlighting the high-margin potential of the specialty therapeutic.
The company’s financial profile reflected the heavy costs associated with a global commercial rollout.
Selling, general and administrative (SG&A) expenses surged to $124.7 million for the eight-month period, compared to $64.9 million in the same period of 2024.
Management attributed this increase to extensive commercialization efforts and pre-commercial awareness campaigns for EKTERLY.
Conversely, research and development (R&D) expenses fell to $33.4 million from $52.2 million a year prior, as major clinical trial activities wound down and certain costs shifted into the commercial SG&A category.
KalVista also maintains a robust capital position to support its growth phase, ending the year with approximately $300.2 million in cash, cash equivalents, and marketable securities.
Notably, the company’s leadership anticipates that this existing liquidity, combined with projected ongoing revenue from EKTERLY sales, will be sufficient to fund operations through to sustained profitability.